By Mill Chart
Last update: Dec 28, 2023
Our stock screener has singled out SANOFI-ADR (NASDAQ:SNY) as a stellar value proposition. NASDAQ:SNY not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. We'll explore this further.
ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:SNY was assigned a score of 7 for valuation:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:SNY has achieved a 8:
ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:SNY was assigned a score of 7 for health:
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:SNY has achieved a 4 out of 10:
More Decent Value stocks can be found in our Decent Value screener.
Check the latest full fundamental report of SNY for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
SANOFI-ADR
NASDAQ:SNY (4/23/2024, 10:43:22 AM)
47.51
+0.36 (+0.76%)
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.
Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.
With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities.